243 related articles for article (PubMed ID: 15251371)
21. Late cytomegalovirus disease following liver transplantation.
Shibolet O; Ilan Y; Kalish Y; Safadi R; Ashur Y; Eid A; Shouval D; Wolf D
Transpl Int; 2003 Dec; 16(12):861-5. PubMed ID: 12904846
[TBL] [Abstract][Full Text] [Related]
22. Risk factors of cytomegalovirus infection after living donor liver transplantation.
Akamatsu N; Sugawara Y; Kaneko J; Kishi Y; Makuuchi M
Hepatogastroenterology; 2005; 52(61):197-9. PubMed ID: 15783029
[TBL] [Abstract][Full Text] [Related]
23. Role of antigenemia assay in the early diagnosis and treatment of CMV infection in renal transplant patients.
Chiaramonte S; Pellizzer G; Rassu M; Dissegna D; Bragantiini L; Zuccarotto D; La Greca G
Clin Nephrol; 2000 Apr; 53(4):suppl 10-2. PubMed ID: 10809428
[TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
25. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
[TBL] [Abstract][Full Text] [Related]
26. [The prevention and treatment of cytomegalovirus infection after liver transplantation].
Zheng SS; Jiang ZJ; Xu X; Liang TB; Wang WL; Shen Y; Zhang M; Lu AW
Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):584-6. PubMed ID: 15938930
[TBL] [Abstract][Full Text] [Related]
27. Is gammaglobulin anti-CMV warranted in lung transplantation?
García-Gallo CL; Gil PU; Laporta R; Carreño MC; de Pablo A; Ferreiro MJ
Transplant Proc; 2005 Nov; 37(9):4043-5. PubMed ID: 16386622
[TBL] [Abstract][Full Text] [Related]
28. [Cytomegalovirus in liver transplantation: incidence and groups at risk].
Schiffer V; Mentha G; Giostra E; Belli D; Le Coultre C; Rohner A
Schweiz Med Wochenschr; 1994 Apr; 124(15):631-6. PubMed ID: 8191266
[TBL] [Abstract][Full Text] [Related]
29. HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.
Härmä M; Loginov R; Piiparinen H; Halme L; Höckerstedt K; Lautenschlager I
Transplant Proc; 2005 Mar; 37(2):1230-2. PubMed ID: 15848678
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
31. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection.
Chen JH; Mao YY; He Q; Wu JY; Lv R
Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078
[TBL] [Abstract][Full Text] [Related]
32. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
33. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.
Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB
Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
Boucher A; Lord H; Collette S; Morin M; Dandavino R
Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
[TBL] [Abstract][Full Text] [Related]
35. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
36. Gancyclovir prophylaxis in high risk patients.
Campino A
Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
[TBL] [Abstract][Full Text] [Related]
37. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients.
Munoz-Price LS; Slifkin M; Ruthazer R; Poutsiaka DD; Hadley S; Freeman R; Rohrer R; Angelis M; Cooper J; Fairchild R; Barefoot L; Bloom J; Fitzmaurice S; Snydman DR
Clin Infect Dis; 2004 Nov; 39(9):1293-9. PubMed ID: 15494905
[TBL] [Abstract][Full Text] [Related]
38. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
39. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
[TBL] [Abstract][Full Text] [Related]
40. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
Winston DJ; Imagawa DK; Holt CD; Kaldas F; Shaked A; Busuttil RW
Transplantation; 1995 Dec; 60(11):1357-60. PubMed ID: 8525537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
